Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vicebio's Avian Influenza (H5) vaccine is a preclinical-stage vaccine candidate designed to protect against the H5N1 strain of avian influenza. The vaccine utilizes Vicebio's proprietary Molecular Clamp technology, which is engineered to stabilize viral fusion proteins, such as the H5 hemagglutinin, in their native pre-fusion conformation. By locking the protein into this highly immunogenic state, the vaccine aims to present the most relevant epitopes to the immune system, thereby inducing a more potent and broad neutralizing antibody response compared to traditional vaccine platforms. This candidate is part of a broader portfolio of respiratory vaccines developed by Vicebio to address pandemic threats and seasonal viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vicebio Avian Influenza (H5) vaccine.